Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation

Leuk Res. 2010 Oct;34(10):1374-82. doi: 10.1016/j.leukres.2009.11.024. Epub 2009 Dec 16.

Abstract

Regulatory T cells (Tregs) can prevent graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT). Here we developed a lentivirus-based strategy to ectopically express Foxp3 in mouse CD4(+)CD25(-) T cells. These cells shared similar immunophenotypes and biological features of natural Tregs. Co-injection of engineered Tregs with donor bone marrow cells and splenocytes prevented recipients from lethal GVHD. Furthermore, we showed that graft-versus-leukemia (GVL) effect against EL4/DsRed leukemic cells was maximally preserved while GVHD was minimized during exposure to engineered Tregs in a mouse leukemia model. These findings provide a novel approach to preventing GVHD while maintaining GVL effect during BMT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow Transplantation / adverse effects*
  • Cells, Cultured
  • Cytokines / blood
  • Forkhead Transcription Factors / genetics*
  • Forkhead Transcription Factors / physiology
  • Graft vs Host Disease / prevention & control*
  • Graft vs Leukemia Effect*
  • Humans
  • Lentivirus / genetics
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • T-Lymphocytes, Regulatory / physiology*
  • Transduction, Genetic

Substances

  • Cytokines
  • FOXP3 protein, human
  • Forkhead Transcription Factors